Journal
STEROIDS
Volume 76, Issue 8, Pages 772-776Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.steroids.2011.02.035
Keywords
Breast cancer; Oestrogen receptor; Endocrine resistance; Aromatase inhibitor; Kinases
Funding
- Mary-Jean Mitchell Green Foundation
- Breakthrough Breast Cancer
- NHS
Ask authors/readers for more resources
Aromatase inhibitors (AI) have improved the treatment of oestrogen receptor positive (ER+) breast cancer. Despite the efficacy of these agents over 40% of patients relapse with endocrine resistant disease. Here we describe an in vitro model of acquired resistance to long-term oestrogen deprivation (LTED). The LTED cells retain expression of the ER and appear hypersensitive to oestrogen as a result of altered kinase activity. Furthermore analysis of temporal changes in gene expression during the acquisition of resistance highlight growth factor receptor pathways as key mediators of this adaptive process. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available